Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Vanguard Real Estate Index Fund ETF trades at $95.14. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Real Estate Index Fund ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VNQ | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $100.95 |
52-Week Low | $555.51 | $87.00 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates impacting real estate valuations, though some analysts see mispricing opportunities in quality REITs during this downturn. Recent institutional selling activity and mixed media sentiment reflect ongoing sector challenges.
The outlook remains cautious as high rates pressure REIT valuations, but selective opportunities exist in digital infrastructure and quality names. Key risks include prolonged high interest rates, economic slowdowns affecting property demand, and competition from alternative income ETFs. Investors should focus on REITs with strong fundamentals and growth potential in evolving sectors like AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
